Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1997 1
1999 2
2000 1
2001 1
2002 1
2003 2
2004 6
2005 1
2006 8
2007 5
2008 5
2009 13
2010 8
2011 10
2012 17
2013 20
2014 20
2015 21
2016 18
2017 27
2018 24
2019 25
2020 31
2021 31
2022 30
2023 18
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31542292

310 results

Results by year

Filters applied: . Clear all
Page 1
Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Matthews DR, et al. Lancet. 2019 Oct 26;394(10208):1519-1529. doi: 10.1016/S0140-6736(19)32131-2. Epub 2019 Sep 18. Lancet. 2019. PMID: 31542292 Clinical Trial.
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA. Frías JP, et al. Lancet Diabetes Endocrinol. 2016 Dec;4(12):1004-1016. doi: 10.1016/S2213-8587(16)30267-4. Epub 2016 Sep 16. Lancet Diabetes Endocrinol. 2016. PMID: 27651331 Clinical Trial.
Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial.
Del Prato S, Foley JE, Kothny W, Kozlovski P, Stumvoll M, Paldánius PM, Matthews DR. Del Prato S, et al. Diabet Med. 2014 Oct;31(10):1178-84. doi: 10.1111/dme.12508. Epub 2014 Jul 17. Diabet Med. 2014. PMID: 24863949 Free PMC article. Clinical Trial.
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, Chow F. Ahrén B, et al. Lancet Diabetes Endocrinol. 2017 May;5(5):341-354. doi: 10.1016/S2213-8587(17)30092-X. Epub 2017 Apr 3. Lancet Diabetes Endocrinol. 2017. PMID: 28385659 Clinical Trial.
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
Lingvay I, Catarig AM, Frias JP, Kumar H, Lausvig NL, le Roux CW, Thielke D, Viljoen A, McCrimmon RJ. Lingvay I, et al. Lancet Diabetes Endocrinol. 2019 Nov;7(11):834-844. doi: 10.1016/S2213-8587(19)30311-0. Epub 2019 Sep 17. Lancet Diabetes Endocrinol. 2019. PMID: 31540867 Clinical Trial.
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article. Review.
310 results